๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hyderabad
Clinical trial register · India

Clinical Trials in Hyderabad

Every study on the ClinicalTrials.gov registry that lists a site in India and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 1123 matching records held by the registry are in this view. Synced 21 Sep 2026, 03:16 UTC
1123
Studies in scope
all four open statuses
610
Recruiting now
open to new participants
222
Lead sponsors
across recruiting studies
Top sites
New Delhi 332 Mumbai 259 Hyderabad 237 Bangalore 193 Pune 189
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Asian Institute of Gastroenterology, India40 AstraZeneca35 Novartis Pharmaceuticals15 Bristol-Myers Squibb15 Eli Lilly and Company14
Site location
New Delhi332 Mumbai259 Hyderabad237 Bangalore193 Pune189
All 274 locations
Target enrolment
to
237 of 1123 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Indian sites
Start
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Bangalore, New Delhi, Hyderabad
2021-09-20
Recruiting
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
NCT04817618C3G
Novartis Pharmaceuticals
Phase 3
98
New Delhi, Hyderabad, Lucknow, Dehradun
2021-07-28
Active, closed
Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2
NCT04229979Acute Myeloid Leukemia
Sellas Life Sciences Group
Phase 3
127
Kannur, Hyderabad, Ludhiฤna, New Delhi, Patna
2021-02-08
Active, closed
A Study of Etavopivat in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)
NCT04624659Sickle Cell Disease
Forma Therapeutics, Inc.
Phase 3
450
Mumbai, Hyderabad, Bangalore, Cutack, New Delhi
2021-01-29
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
Novartis Pharmaceuticals
Phase 4
1,000
Surat, Bangalore, Mumbai, Nashik, New Delhi, Hyderabad
2020-12-22
Active, closed
Atrasentan in Patients With IgA Nephropathy
NCT04573478IgA Nephropathy, Immunoglobulin A Nephropathy
Novartis Pharmaceuticals
Phase 3
404
Kozhikode, Pune, Vellore, Hyderabad, Secunderabad, Kolkata
2020-12-11
Recruiting
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
NCT04613596Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Mirati Therapeutics Inc.
Phase 2/3
626
Ahemdabad, Ahmedabad, Aurangabad, Bangalore, Belagavi, Howrah, Hyderabad, Jaipur
2020-12-02
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
Amgen
Phase 3
238
Nagpur, Hyderabad, Bangalore, Lucknow, Manipal, Nashik, Pune, Surat
2020-10-15
Active, closed
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
NCT04538664Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
308
Hyderabad, Kolkata, Mumbai, Nashik, New Delhi, Pune
2020-10-13
Active, closed
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT04487080Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 3
1,074
Hyderabad, Kolkata, Mumbai, Nashik, Pune
2020-09-30
Recruiting
A Study of EPX-100 (Clemizole Hydrochloride) in Participants With Dravet Syndrome
NCT04462770Dravet Syndrome
Epygenix
Phase 3
150
Hyderabad, Surat, Belagavi, Bengaluru, Kochi, Pune, Mumbai, Nagpur
2020-09-15
Active, closed
MINIject Global Long-Term Follow-up Study
NCT04524416Open Angle Glaucoma, Ocular Hypertension
iSTAR Medical
Observational
116
Hyderabad
2020-08-05
Active, closed
A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)
NCT03992430Muscular Dystrophy, Duchenne
Sarepta Therapeutics, Inc.
Phase 3
160
Ahmedabad, Bengaluru, Hyderabad, Madurai, New Delhi, Pune, Vellore
2020-07-13
Active, closed
Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naรฏve Subjects With Active Psoriatic Arthritis II (INSPIRE 2)
NCT04314531Active Psoriatic Arthritis
Sun Pharmaceutical Industries Limited
Phase 3
296
Surat, Bangalore, Belagavi, Hubli, Pune, Hyderabad, Lucknow, Kochi
2020-07-01
Active, closed
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
NCT04273945Pulmonary Arterial Hypertension
Actelion
Phase 3
935
Ahmedabad, Bangalore, Chengalpetu, Coimbatore, Durgapur, Hyderabad, Hyderbad, Kolkata
2020-06-30
Recruiting
Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (ฮฒ)-Thalassemia
NCT04143724Beta-Thalassemia
Celgene
Phase 2
99
Hyderabad, Mumbai, Nagpur, Noida, Kolkata, Vellore
2019-11-07
Active, closed
Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NCT03983954ER+ Breast Cancer, Ovarian Cancer, Cervical Squamous Cell Carcinoma, Pancreatic Adenocarcinoma
NeoTX Therapeutics Ltd.
Phase 1
120
Ahmedabad, Jhajjar, New Delhi, Udaipur, Hyderabad
2019-10-10
Active, closed
SyncAV Post-Market Trial
NCT04100148Congestive Heart Failure
Abbott Medical Devices
Not applicable
1,686
Hyderabad, Ahmedabad, Bangalore, Gurgaon, New Delhi
2019-10-03
Active, closed
Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients
NCT03814746Sickle Cell Disease (SCD)
Novartis Pharmaceuticals
Phase 3
254
Bhubaneswar, Hyderabad
2019-07-26
Active, closed
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
NCT03769506Head and Neck Cancer
Rakuten Medical, Inc.
Phase 3
135
Vadodara, Bangalore, Kochi, Chennai, Hyderabad, Kolkata, Mumbai
2019-05-09
Active, closed
PROSpect: Prone and Oscillation Pediatric Clinical Trial
NCT03896763Acute Respiratory Distress Syndrome in Children
University of Pennsylvania
Not applicable
600
Hyderabad
2019-05-01
Active, closed
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
NCT03847428Hepatocellular Carcinoma
AstraZeneca
Phase 3
908
Bangalore, Hyderabad, Kolkata, Mumbai, New Delhi
2019-04-29
Active, closed
Intra-operative Pancreatoscopy in Patients With IPMN
NCT03729453Intraductal Papillary Mucinous Neoplasm
Boston Scientific Corporation
Observational
100
Hyderabad
2019-03-20
Active, closed
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,882
Mangalore, Kochi, Mumbai, Pune, New Delhi, Chandigarh, Hyderabad, Howrah
2018-12-28
Active, closed
A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma
NCT03778957Hepatocellular Carcinoma
AstraZeneca
Phase 3
724
Bangalore, Bengaluru, Hyderabad, Kolkata, Madurai, Mumbai, Nashik, Pune
2018-11-30
Rows per page Showing 201–225 of 237
Previous 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Indian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 21 September 2026. https://priyalifescience.com/clinical-trials-india/city/hyderabad

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.